This site contains promotional content intended for UK Healthcare Professionals and other relevant decision makers | Not a HCP? Visit our  Public Site.

Adverse Event reporting can be found at the bottom of the page | Prescribing Information for the relevant medicine can be found adjacent to the below content and/or in the footer below. 

  • Products
  • Therapy Areas
  • Resources
  • Events & Webinars
  • Learning Zone
  • Podcasts
EYLEA 8 mg Hero Banner

Real World Experience

with EYLEA® (aflibercept) 8 mg

EYLEA 114.3 mg/mL is indicated in adults for the treatment of neovascular (wet) age-related macular degeneration (nAMD), visual impairment due to diabetic macular oedema (DMO) and visual impairment due to macular oedema secondary to retinal vein occlusion (branch, central and hemiretinal RVO).

 

Explore the real-world experiences of UK clinicians implementing EYLEA® (aflibercept) 8 mg, highlighting its potential to address unmet needs in the treatment of nAMD, DMO and RVO.

Confidence in Every Dose

Webinar 2: Real-World Outcomes with EYLEA 8 mg

Explore our second 'Confidence in Every Dose' webinar through

bite-sized videos
where UK speakers share their insights on audits and patient datasets related to EYLEA 8 mg.

RVO 12-month Audit: Aalborg University Hospitals, Denmark

 

In this video,

Lasse Cehofski
presents 12-month audit results using EYLEA 8 mg for patients with RVO.

  • Duration: ~8 minutes
  • 68 treatment-naïve & 156 treatment-experienced eyes
  • RVO

Prescribing information for EYLEA® (aflibercept)

can be found here
.

Latest UK Audits of EYLEA 8 mg

These UK audit videos highlight the real life usage of EYLEA 8 mg within leading ophthalmology clinics. Watch these videos to learn more about the impact of EYLEA 8 mg on patient care and clinical practice.

York and Scarborough Teaching Hospitals NHS Foundation Trust

 

In this video,

Richard Gale
presents EYLEA 8 mg audit data from York and Scarborough Teaching Hospitals NHS Foundation Trust, discussing the impact of EYLEA 8 mg in treatment-naïve and previously treated nAMD and DMO patients, summarising the importance of liberating clinical capacity. 

  • Duration: ~10 minutes
  • nAMD: 59 treatment-naïve eyes & 142 treatment-experienced eyes
  • DMO: 9 treatment-naïve eyes & 39 treatment-experienced eyes
  • nAMD & DMO

Prescribing information for EYLEA® (aflibercept)

can be found here
.

PDF Case Studies

View/download EYLEA® (aflibercept) 8 mg case studies from medical retina centres across the UK & beyond.

Imperial College Healthcare NHS Trust (DMO)
Imperial College Healthcare NHS Trust (nAMD)
IRIS Registry and Vestrum Health Retina Database (Naïve / nAMD)
York and Scarborough Teaching Hospitals NHS Foundation Trust (DMO)
York and Scarborough Teaching Hospitals NHS Foundation Trust (nAMD)
IRIS Registry and Vestrum Health Retina Database (Previously treated / nAMD & DMO)
South Tyneside and Sunderland NHS Foundation Trust (Previously treated / nAMD)
NHS Greater Glasgow and Clyde (Previously treated / nAMD)
Swiss Retina Research Network (SRRN)
The Royal Wolverhampton NHS Trust (nAMD)
University Hospitals Bristol and Weston NHS Foundation Trust (Naïve / nAMD)
SPECTRUM Study
University Hospitals of Leicester NHS Trust (Previously treated / nAMD)
Moorfields Eye Hospital, Bedford Hospitals NHS Trust (Naïve / nAMD)

Confidence in Every Dose

Webinar 1: Real-World Outcomes with EYLEA 8 mg

Explore our 'Confidence in Every Dose' webinar through

bite-sized videos
where UK speakers share their insights on audits and patient datasets related to EYLEA 8 mg.

The Royal Wolverhampton NHS Trust and NHS Greater Glasgow and Clyde

 

In this video,

Niro Narendran
presents EYLEA 8 mg audit results from the Royal Wolverhampton NHS Trust and NHS Greater Glasgow and Clyde.
The Royal Wolverhampton NHS Trust:
 An audit of 20 treatment-experienced eyes that were switched to EYLEA 8 mg. Prior to the switch, these patients had undergone extensive therapy, averaging 40 previous anti-VEGF injections each.
NHS Greater Glasgow and Clyde
: An audit of 39 treatment-experienced eyes that were switched to EYLEA 8 mg.

  • Duration: ~4 minutes
  • Treatment-experienced patients
  • nAMD

Prescribing information for EYLEA® (aflibercept)

can be found here
.

International Medical Retina Congress Highlights on EYLEA 8 mg

These short videos feature insights from a variety of clinicians who are using EYLEA 8 mg and highlight key learnings and updates from recent congresses.

Connect with us!
If you find these videos helpful, we invite you to stay updated on the latest resources regarding EYLEA 8 mg, including highlights from international congresses. Click below to reach out to us or to register for our communications!

Contact us here

American Academy of Ophthalmology (AAO) Congress | October 2025

 

In this 5-minute video,

Helen Devonport
(Consultant Ophthalmologist, Bradford Teaching Hospitals NHS Foundation Trust) presents the real-world use of EYLEA 8 mg for treatment-naïve and treatment experienced patients with nAMD and DMO from the IRIS Registry.

Prescribing information for EYLEA® (aflibercept)

can be found here
.

Abbreviations

DMO, diabetic macular oedema. HCP, healthcare professional. nAMD, neovascular (wet) age-related macular degeneration. NHS, National Health Service. RVO, retinal vein occlusion. RWE, real-world evidence. SmPC, Summary of Product Characteristics. UK, United Kingdom. VEGF, vascular endothelial growth factor.

Prescribing information for EYLEA® (aflibercept)

can be found here
.

PP-EYL-GB-3169 | June 2026

    • 1
      EYLEA® 114.3 mg/mL Summary of Product Characteristics.